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IntroductIon: Pre-pregnancy overweight and obesity have been proposed as 
risk factor to diabetes and hypertension during pregnancy. These medical com-
plications enhance the economic burden related to attend the pregnancy when 
it is classified as high risk pregnancy. objectIves: Identify diseases related to 
pre-gestational overweight and obesity in women with high risk pregnancy and 
estimate the economic burden to attend high risk pregnancy compared with nor-
mal pregnancy Methods: Were studied 600 patients with high risk pregnancy to 
identify pre-pregnancy overweight and obesity and were estimated the cost related 
to the medical health care during pregnancy. Were calculated: mean, standard 
deviation, median, percentilar values, logistic regression and Odds Ratio with 
95% confidence interval. Were estimated costs for a hypothetical group of 600 
women with normal pregnancy, using Monte Carlo simulation method to compare 
economic burden between high risk pregnancy and normal pregnancy. Statistical 
differences were calculated with Student T test to paired samples. Groups were 
paired by maternal age and gestational age. results: Pre-pregnancy body mass 
index mean was 29.59 (±6.42)kg/m2. The obesity was a risk factor to develop ges-
tational diabetes (OR: 1.95; IC95%: 1.39 to 2.76; p= 0.000). Were estimated in USD, 
to following costs: mean cost for prenatal health care: [$165.28 (±$52.39) in nor-
mal pregnancy; $801.18 (±$272.14), for high risk pregnancy, p= 0.000], mean cost 
for laboratory test [$ 138.41 (±$32.12) normal pregnancy; $895.91 (±$304.32) high 
risk pregnancy (p= 0.000)], delivery cost [$748.39 (±$340.51) normal pregnancy; 
$1,762.60 (±$513.88), p= 0.000 high risk pregnacy] and mean total cost $2,514.86 
(±$852.57), in normal pregnancy and $6,800.34 (±$3,829.82) high risk pregnancy 
(p= 0.000). conclusIons: 75% pregnant women reach the pregnancy with preges-
tational overweight or obesity, and these conditions are risk factor to medical 
complications during pregnancy with significant higher costs derived from health 
care during pregnancy respect to women with normal pregnancy without pre-
pregnancy overweight or obesity
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objectIves: To compute the annual cost of FDC drugs used in the treatment of 
Type2 Diabetes Mellitus (T2DM) and study the variation in the costs. Methods: 
Indian Council of Medical Research (ICMR) and International Diabetes Federation 
(IDF) guidelines were used to understand the treatment of T2DM. Current Index of 
Medical Specialities (CIMS) Oct- Jan 2015 issue and Indian Drug Review (IDR) issue 
1, Jan 2015 were used to capture the prices of medicines available in the Indian 
market. The annual cost of treatment and variation in the annual cost of drugs was 
studied. results: Recommended first line FDC according to International Diabetes 
Federation is metformin + sulfonylurea. If we initiated the treatment with met-
formin + glimepiride (500mg + 1mg) OD, then annual cost of treatment was found 
to be Rs.438-2744. A maximum variation of 533% was noted in the least-highest cost 
of treatment. A minimum of 1% variation was observed for metformin + glipizide 
(2.5mg + 400mg) OD, among combination therapy in its least-highest cost of treat-
ment. Likewise, if the treatment is initiated with other combination therapy, say 
metformin + pioglitazone (500mg +15mg) BD, then annual cost of treatment was 
found to be Rs.1387-6935. This showed a maximum variation of 665% in its least-
highest cost of treatment. On the other hand metformin + voglibose (500 + 0.3mg) 
combination showed a minimum price variation of 86% only. conclusIons: It was 
concluded that a maximum of 6 fold variation was observed in the least-highest 
costs of treatment with metformin + voglibose (500mg + 0.3mg). A wide varia-
tion exist in the minimum and maximum price of anti-diabetic FDC manufactured 
across the different brands available in the Indian market.
PDB31
eConomiC AsPeCts in the mAnAgement of DiABetes in itAly
Marcellusi A1, Viti R2, Sciattella P2, Aimaretti G3, De Cosmo S4, Provenzano V5, Tonolo G6, 
Mennini FS1
1Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation 
and HTA (EEHTA), University of Rome, Rome, Italy, 2University of Rome “Tor Vergata” Italy, Rome, 
Italy, 3University of Eastern Piedmont, Vercelli, Italy, 4“Casa Sollievo della Sofferenza” Hospital, 
San Giovanni Rotondo, Italy, 5Hospital of Partinico, Palermo, Italy, 6ASL Olbia, Olbia, Italy
objectIves: Diabetes Mellitus (DM) is a chronic-degenerative disease associated 
with a high risk of chronic complications and co-morbidities. The aim of this study 
is to estimate the average annual cost incurred by the National Health Service 
(NHS) for the treatment of DM stratified by patients’ comorbidities. Moreover, the 
model estimate the economic impact implementing good clinical practice for the 
management of diabetic patients. Methods: Data were extrapolated from admin-
istrative database of the Marche Region and specific inclusion and exclusion criteria 
were developed from clinical board in order to estimate patients with DM only, 
DM+1, DM+2, DM+3 and DM+4 comorbidities (cardiovascular disease, neuropathy, 
nephropathy and retinopathy). Regional data were considered a good proxy for 
implementing a previous developed Cost of Illness model from NHS perspective 
already published. Scenario analysis were considered to estimate the economic 
impact of good clinical practice implementation in the treatment of DM and its 
comorbidities in Italy. results: The model estimated an average number of dia-
betic patients per year in the Marche region of 86.155 (5.5% of population) from 
2008-2011. Mean costs per patients with DM only, DM+1, DM+2, DM+3 and DM+4 
comorbidities were € 179, € 1,560, € 2,736, € 8,494 and € 21,321, respectively. From the 
NHS perspective, the total economic burden of DM in Italy amounted to € 8.5 billion/
year (22% for drugs, 74% for hospitalization and 4% for visits). Scenario analysis 
demonstrate that implementation of good clinical practice could save over € 700 
million year. conclusIons: This model is the first study that consider real world 
data and CoI model to estimate the economic burden of DM and its comorbidities 
from the NHS perspective. Integrated management of the diabetic patient could be 
a good driver for the reduction of the costs of this disease in Italy.
4,282 saxagliptin and 1,286 linagliptin) and 3,229 patients with Commercial coverage 
(2,368 sitagliptin; 643 saxagliptin and 218 linagliptin). Patient demographics were 
similar for index medications: Medicare cohort – mean age 70-72; female 50-52% 
Commercial cohort – mean age 55-56; female 44%. Patients on linagliptin showed 
a higher co-morbidity level at baseline (Medicare DCSI = 3.0 vs 2.4/2.2; Commercial 
DCSI = 1.2 vs. 0.9/0.9), higher use of pre-index insulin (Medicare 22% vs 15%/14%; 
Commercial 18% vs 11%/10%) and higher pre-index costs (Medicare mean $14,448 vs 
$11,818/$10,399; Commercial mean $13,868 vs $9,357/$8,223) than sitagliptin or saxa-
gliptin cohorts, respectively. When controlling for other factors, post-index costs were 
similar between the medication cohorts - Medicare: sitagliptin $13,913; saxagliptin 
$13,651; linagliptin $13,859; Commercial: sitagliptin $11,677; saxagliptin$12,059; lina-
gliptin $11,163. conclusIons: For Medicare and Commercial populations, members 
on linagliptin may have been more complex patients (higher DCSI, more use of insulin, 
higher pre-index costs). When controlling for baseline factors, 12-month post-index 
direct medical costs were similar between index DPP4 medications.
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objectIves: to compare the healthcare utilization and costs in the year before and 
after randomization among participants of a clinical trial assessing the effective-
ness of nurse-led telecoaching in optimizing diabetes control in Belgium. Methods: 
Patients were affiliates of the Independent Sickness Funds with type 2 diabetes 
selected by hypoglycaemic agent consumption, invited into the study and randomized 
to telecoaching or usual care. The intervention was delivered by diabetes educators 
in five telephone sessions spread over 6 months. Costs of the intervention were col-
lected along the trial. Information on resource utilization was extracted from the 
database of the sickness funds and the between group difference in change was 
analyzed per service category. results: 287 patients enrolled in the intervention 
and 287 in the control group. The average cost of the intervention was € 300.64. At 
baseline, the annual mean healthcare cost (CI) was € 5,543 (4,410–6,677) in the inter-
vention and € 4,101 (3,375–4,827) in the control group and in the year of the trial € 5,516 
(4,630 –6,402) and 4,757 (3,892–5,622), implying a change of -1% and +16% respectively. 
Hospitalizations affected 19% and 15% of patients in the intervention and control 
group, accounting for 33% and 23% of total costs at baseline, respectively. In the year 
of the trial, changes were observed in the intervention and control group respec-
tively in the number of hospital admissions: -27% and +36% (p= .048), endocrinologist 
consultations: +35% and -10% (p= .023), HbA1c tests: +9% and -12% (p< .0001), lipid 
tests: +8% and -16% (p< .0001) and consumption of lipid modifying agents: +14% and 
+1% (p= .042). conclusIons: Participants of the nurse-led telecoaching program 
aimed at improvement of diabetes selfmanagement demonstrated increased costs for 
guideline recommended outpatient care and a decrease in the number and costs of 
hospital admissions compared to controls. These findings are hypothesis generating.
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objectIves: To compare drug acquisition costs and most commonly used doses 
between two GLP-1 agonists, once-weekly exenatide (QW) 2.0 mg with no dose titra-
tion, and once-daily liraglutide with a recommended starting dose of 0.6 mg and 
titration to 1.2 mg or 1.8 mg over 2-weeks. Methods: This cohort study included 
patients with type 2 diabetes initiating exenatide QW or liraglutide between Jan 2012 
and Feb 2014, who had > 6-months of preceding coverage in U.S. healthcare claims 
database. During the 6 months following treatment initiation, drugs dispensed and 
associated pharmacy costs were compared between exenatide QW 2 mg dose and 
liraglutide dose subgroups, defined by maintenance dose at 60 days. results: The 
exenatide QW (N= 3,217) and liraglutide (N= 10,954) cohorts had comparable charac-
teristics at baseline. Due to titration recommendations, the majority of the liraglu-
tide patients received 1.8 mg per day dose (56.2%), while 2.2% and 41.6% received 0.6 
mg and 1.2 mg per day, respectively, by the end of follow-up. Comparing costs asso-
ciated with exenatide QW versus specific liraglutide maintenance doses, patients 
on liraglutide 1.8 mg per day had higher average pharmacy costs of $3,827 (95%CI: 
$3,752-$3,902) compared to exenatide QW costs of $3,556 (95% CI: $3,462-$3,649), and 
higher average pharmacy costs associated with all antihyperglycemic drug dispens-
ings, $2,543 (95%CI: $2,502 - $2,585), compared to exenatide QW costs $2,345 (95%CI: 
$2,290 - $2,401). conclusIons: Exenatide QW, which does not require titration, 
provided savings in both overall pharmacy costs and costs of antihyperglycemic 
drugs compared to the majority (56.2%) of liraglutide patients who required titration 
to the highest dose of 1.8 mg. Lower pharmacy costs in addition to overall safety 
and efficacy profile, convenience of no titration, and once weekly dosing, provide a 
good cost-benefit value for patients treated with exenatide QW.
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